SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose Passive 0.4% Stake in RAPT Therapeutics Inc.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, confirming a passive beneficial ownership of 0.4% of RAPT Therapeutics Inc.'s common stock as of January 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson are the reporting persons in this Schedule 13G Amendment No. 6 filing.
• As of January 31, 2025, they collectively beneficially own 480,507 shares of RAPT THERAPEUTICS INC common stock.
• This ownership represents 0.4% of the total outstanding class of securities.
• FMR LLC holds sole voting power over 471,807 shares and sole dispositive power over 480,507 shares.
• Abigail P. Johnson holds sole dispositive power over 480,507 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of RAPT Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document is a routine, factual disclosure of beneficial ownership and does not contain information that would significantly alter the perceived sentiment towards the issuer or the reporting entity beyond confirming a passive investment.

Positives

• The filing confirms that FMR LLC and Abigail P. Johnson hold their stake in the ordinary course of business and not for the purpose of changing or influencing control of RAPT Therapeutics Inc., indicating a stable, passive investment.

Negatives

• The beneficial ownership of 0.4% is a relatively small, non-controlling stake, which means the reporting persons do not have significant influence over the company's strategic direction.

Future Outlook

This document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding RAPT Therapeutics Inc.'s future performance or outlook.

Industry Context

This filing is a routine disclosure of a passive investment stake by a major institutional investor (FMR LLC) in a biotechnology company, RAPT Therapeutics Inc. It does not provide specific insights into broader industry trends or competitive dynamics beyond the fact that FMR LLC holds a small, non-controlling position in this sector.

Stakeholder Impact

• Shareholders: The filing indicates that a significant institutional investor, FMR LLC, maintains a passive, non-controlling stake in RAPT Therapeutics Inc., which may be viewed as a vote of confidence in the company's long-term prospects, albeit without direct influence on management or strategy.

Key Dates

Keywords

RAPT THERAPEUTICS INC, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, passive investment, institutional investor